# A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

> clinical trial · VERIFIED · 2026-06-16

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

- Company: Novartis Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07226986

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.